Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Medpace Holdings Inc (MEDP) Price & Performance

YieldMax AI & Tech Portfolio Option Income ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AI & Tech Portfolio Option Income ETF vs Medpace Holdings Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.

GPTYMEDP
Sector
Income / Options OverlayTechnology
52-Week High
$50.52$620.59
52-Week Low
$34.73$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AI & Tech Portfolio Option Income ETF

GPTY trades at $42.99, up 0.79% on the day, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 at 83.06 suggests overbought conditions. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.28 to $0.38, highlighting its income-focused approach through option premiums on AI and tech equities.

Outlook remains positive due to strong AI theme exposure and income generation, but risks include reliance on semiconductor momentum and potential NAV erosion from option strategies. Investors benefit from high yield but face volatility tied to tech sector performance.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AI & Tech Portfolio Option Income ETF

GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.

Read more on GPTY

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP